Actively Recruiting

Age: 18Years +
All Genders
NCT06578650

A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms

Led by Acera Surgical, Inc. · Updated on 2025-05-28

34

Participants Needed

1

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this observational prospective study is to evaluate wound healing outcomes in resection wounds resulting from surgical removal of cutaneous malignancies treated with a synthetic electrospun fiber matrix. This study intends to quantify the time from initial resection and product application to time of complete granulation of the wound bed in weeks.

CONDITIONS

Official Title

A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is at least 18 years old
  • Patient plans to undergo surgical resection of a cutaneous neoplasm
  • Patient is willing and capable of complying with all protocol requirements
  • Patient or legally authorized representative is willing to provide written informed consent
  • Post-resection surgical wound with a surface area of 64 cm2 and 6 36 cm2
Not Eligible

You will not qualify if you...

  • Inability to give informed consent or complete study procedures
  • Previously enrolled in this study or participating in another ongoing drug or device study
  • Pregnant, breastfeeding, or planning pregnancy
  • Known allergy to resorbable suture materials like Polyglactin 910 or Polydioxanone
  • Received immunotherapy, radiation, or chemotherapy within 4 weeks prior to surgery
  • Life expectancy less than 6 months
  • Additional wound within 3 cm of study wound
  • Study wound located on hands or feet
  • Diagnosed with osteomalacia
  • Resection defect from squamous cell carcinoma arising from chronic wound
  • Uncontrolled thyroid disorder
  • Hgb A1c > 12% within 3 months prior for diabetic patients
  • BMI over 34.9
  • Used tobacco products within 30 days prior to surgery
  • Chronic kidney disease on dialysis or very low kidney function
  • Severe liver disease with active cirrhosis or high MELD-Na score
  • Poor metabolic control as judged by investigator
  • History of poor compliance with medical treatment
  • History of radiotherapy to wound bed
  • Diagnosed with autoimmune connective tissue diseases like lupus, vasculitis, sickle cell, or uncontrolled rheumatoid arthritis
  • Active infection, undrained abscess, or critically colonized wound as judged by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Nevada - Las Vegas

Las Vegas, Nevada, United States, 89102

Actively Recruiting

Loading map...

Research Team

M

Matthew MacEwan, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here